TGA grants approval for oral Wegovy weight-loss tablet in Australia
सिर्फ तथ्य

TGA grants approval for oral Wegovy weight-loss tablet in Australia

सारांश

The Therapeutic Goods Administration has approved a daily pill version of Wegovy, expanding treatment options for adults with obesity and marking the first oral GLP-1 therapy approved in the country.

The Therapeutic Goods Administration approved an oral tablet form of the weight-loss drug Wegovy on Tuesday, giving Australians a daily pill alternative to the weekly injections currently used. The tablet, developed by Novo Nordisk, is available in four dosage strengths – 1.5 mg, 4 mg, 9 mg and 25 mg – and is prescribed for adults with clinical obesity or those requiring treatment to lower cardiovascular risk.

"Novo is working towards bringing this new treatment option to eligible Australians, with anticipated availability later this year. We will share confirmed availability timing as soon as we can," a Novo Nordisk spokeswoman told the Australian Financial Review.

Novo Nordisk said it aims to launch the product in Australia before the end of the year, though the TGA must still complete final checks on manufacturing and packaging to ensure domestic quality standards are met. Industry analysts expect the tablet could boost the number of users by up to 40 percent, following similar demand spikes seen in the United States and Europe after oral formulations were approved.

Recent data from intelligence firm Nostradata indicate that 1.6 million Australians purchased a GLP-1 medication privately over the past year, roughly double earlier estimates of active monthly users. While the retail price for the tablet has not yet been announced, current out-of-pocket costs for injectable GLP-1 treatments can reach $600 per month. The approval also comes as competition intensifies, with US drugmaker Eli Lilly seeking TGA clearance for its own oral candidate, Orforglipron.

स्रोत

Nine.com.au

पढ़ते रहें — निःशुल्क

समाचार फ़ॉलो करने के लिए मुफ़्त खाता बनाएँ। कार्ड की आवश्यकता नहीं।